CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.
Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
异基因造血干细胞移植(alloSCT)是许多血液系统恶性肿瘤的唯一治愈手段。然而,alloSCT受者易受机会性病原体感染,如人巨细胞病毒(HCMV)。来特莫韦预防已彻底改变了HCMV管理,但晚期HCMV再激活的挑战已经出现。停用来特莫韦后临床显著HCMV感染(csCMVi)的免疫学替代标志物仍有待明确。
因此,我们在24例alloSCT受者的来特莫韦预防停止前(第+90天)和停止后(第+120-270天)的7个时间点,研究了自然杀伤(NK)细胞重建以及整体和HCMV pp65特异性T细胞库。发生csCMVi的患者IFN-+ HCMV特异性CD4+和CD8+ T细胞计数低于HCMV控制者。
此外,csCMVi患者表现出NK细胞重建的晚期受损,尤其是“记忆样”CD159c+CD56dim NK细胞计数的抑制,这在大多数患者中先于csCMVi事件出现。
此外,若干免疫重建替代标志物与HCMV表现的严重程度相关,患有HCMV终末器官疾病和/或难治性HCMV感染的患者携带最少的HCMV特异性T细胞和“记忆样”NK细胞。
总之,我们的研究结果确立了HCMV特异性T细胞和“记忆样”NK细胞增殖延迟或不足与停用来特莫韦预防后csCMVi及HCMV表现严重程度之间的关联。
Allogeneic hematopoietic stem cell transplantation (alloSCT) is the only cure for many hematologic malignancies.
However, alloSCT recipients are susceptible to opportunistic pathogens, such as human cytomegalovirus (HCMV). Letermovir prophylaxis has revolutionized HCMV management, but the challenge of late HCMV reactivations has emerged. Immunological surrogates of clinically significant HCMV infection (csCMVi) after discontinuation of letermovir remain to be defined.
Therefore, we studied natural killer (NK)-cell reconstitution along with the global and HCMV pp65-specific T-cell repertoire of 24 alloSCT recipients at 7 time points before (day +90) and after (days +120-270) cessation of letermovir prophylaxis. Patients who experienced csCMVi had lower counts of IFN- + HCMV-specific CD4+ and CD8+ T cells than HCMV controllers.
Furthermore, patients with csCMVi displayed late impairment of NK-cell reconstitution, especially suppression of "memory-like" CD159c+CD56dim NK-cell counts that preceded csCMVi events in most patients.
Moreover, several surrogates of immune reconstitution were associated with the severity of HCMV manifestation, with patients suffering from HCMV end-organ disease and/or refractory HCMV infection harboring least HCMV-specific T cells and "memory-like" NK cells. Altogether, our findings establish an association of delayed or insufficient proliferation of both HCMV-specific T cells and "memory-like" NK cells with csCMVi and the severity of HCMV manifestations after discontinuation of letermovir prophylaxis.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。